Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04277637 · ClinicalTrials.gov registry record · Phase 1
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
A Phase 1 study of Mature B-cell Malignancies, sponsored by BeiGene.
- Active
- Registry status
- Phase 1
- Development phase
- 437
- Enrollment target
- 20
- Study locations
NCT04277637 is a Phase 1 study of Mature B-cell Malignancies that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 437 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT04277637, a Phase 1 study of Mature B-cell Malignancies, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 437 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Obinutuzumab
- DRUG Sonrotoclax
Study Locations (20)
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center Mskcc - New York
New South Wales
- Concord Repatriation General Hospital - Concord
- Orange Health Service (Central West Cancer Care Centre) - Orange
Queensland
- Pindara Private Hospital - Benowa
- John Flynn Private Hospital - Tugun
South Australia
- Royal Adelaide Hospital - Adelaide
- Flinders Medical Centre - Bedford PK
California
- UCLA Hematologyoncology - Los Angeles
Illinois
- Northwestern University - Chicago
Kansas
- University of Kansas Medical Center Research Institute - Kansas City
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2020-03-24 |
| Est. Completion | 2027-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04277637
The ClinicalTrials.gov registry entry for NCT04277637 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 437 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mature B-cell Malignancies appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.
NCT04277637 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, New South Wales, Queensland.
Frequently Asked Questions
What is clinical trial NCT04277637 about?
NCT04277637 is a clinical study titled "Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies". The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination w...
What is the current status of trial NCT04277637?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 437 participants. The study started on 2020-03-24. Estimated completion is 2027-08-30.
What conditions does trial NCT04277637 study?
This clinical trial studies the following conditions: Mature B-cell Malignancies.
What interventions are being tested in trial NCT04277637?
The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG), Sonrotoclax (DRUG).
Who is sponsoring clinical trial NCT04277637?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04277637 being conducted?
This trial has 20 study locations across California, Illinois, Kansas, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mature B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.